Download PDF
Semin Liver Dis 2023; 43(01): 117-132
DOI: 10.1055/a-2015-1290
Review Article

Cirrhosis Management in the Intensive Care Unit

Thomas N. Smith
1   Department of Internal Medicine, Mayo Clinic Rochester, Rochester, Minnesota
,
Alice Gallo de Moraes
2   Division of Pulmonary and Critical Care Medicine, Mayo Clinic Rochester, Rochester, Minnesota
,
Douglas A. Simonetto
3   Division of Gastroenterology and Hepatology, Mayo Clinic Rochester, Rochester, Minnesota
› Author Affiliations Funding None.
› Further Information
    Permissions and Reprints


Abstract

Patients with cirrhosis frequently require admission to the intensive care unit as complications arise in the course of their disease. These admissions are associated with high short- and long-term morbidity and mortality. Thus, understanding and characterizing complications and unique needs of patients with cirrhosis and acute-on-chronic liver failure helps providers identify appropriate level of care and evidence-based treatments. While there is no widely accepted critical care admission criteria for patients with cirrhosis, the presence of organ failure and primary or nosocomial infections are associated with particularly high in-hospital mortality. Optimal management of patients with cirrhosis in the critical care setting requires a system-based approach that acknowledges deviations from canonical pathophysiology. In this review, we discuss appropriate considerations and evidence-based practices for the general care of patients with cirrhosis and critical illness.

Keywords

cirrhosis - critical care - acute-on-chronic liver failure - sepsis


Publication History

Accepted Manuscript online:
18 January 2023

Article published online:
13 February 2023

© 2023. Thieme. All rights reserved.

Thieme Medical Publishers, Inc.
333 Seventh Avenue, 18th Floor, New York, NY 10001, USA

 

  • References

  • 1 Tapper EB, Parikh ND. Mortality due to cirrhosis and liver cancer in the United States, 1999-2016: observational study. BMJ 2018; 362: k2817
    CrossrefPubMedGoogle Scholar
  • 2 Moon AM, Singal AG, Tapper EB. Contemporary epidemiology of chronic liver disease and cirrhosis. Clin Gastroenterol Hepatol 2020; 18 (12) 2650-2666
    CrossrefPubMedGoogle Scholar
  • 3 Scaglione S, Kliethermes S, Cao G. et al. The epidemiology of cirrhosis in the United States: a population-based study. J Clin Gastroenterol 2015; 49 (08) 690-696
    CrossrefPubMedGoogle Scholar
  • 4 Allen AM, Kim WR, Moriarty JP, Shah ND, Larson JJ, Kamath PS. Time trends in the health care burden and mortality of acute on chronic liver failure in the United States. Hepatology 2016; 64 (06) 2165-2172
    CrossrefPubMedGoogle Scholar
  • 5 Olson JC, Wendon JA, Kramer DJ. et al. Intensive care of the patient with cirrhosis. Hepatology 2011; 54 (05) 1864-1872
    CrossrefPubMedGoogle Scholar
  • 6 Majumdar A, Bailey M, Kemp WM, Bellomo R, Roberts SK, Pilcher D. Declining mortality in critically ill patients with cirrhosis in Australia and New Zealand between 2000 and 2015. J Hepatol 2017; 67 (06) 1185-1193
    CrossrefPubMedGoogle Scholar
  • 7 Ginès P, Krag A, Abraldes JG, Solà E, Fabrellas N, Kamath PS. Liver cirrhosis. Lancet 2021; 398 10308 1359-1376
    CrossrefPubMedGoogle Scholar
  • 8 D'Amico G, Garcia-Tsao G, Pagliaro L. Natural history and prognostic indicators of survival in cirrhosis: a systematic review of 118 studies. J Hepatol 2006; 44 (01) 217-231
    CrossrefPubMedGoogle Scholar
  • 9 Trebicka J, Fernandez J, Papp M. et al; PREDICT STUDY Group of the EASL-CLIF Consortium.. The PREDICT study uncovers three clinical courses of acutely decompensated cirrhosis that have distinct pathophysiology. J Hepatol 2020; 73 (04) 842-854
    CrossrefPubMedGoogle Scholar
  • 10 Sarin SK, Choudhury A, Sharma MK. et al; APASL ACLF Research Consortium (AARC) for APASL ACLF Working Party.. Acute-on-chronic liver failure: consensus recommendations of the Asian Pacific association for the study of the liver (APASL): an update. Hepatol Int 2019; 13 (04) 353-390
    CrossrefPubMedGoogle Scholar
  • 11 Jalan R, Saliba F, Pavesi M. et al; CANONIC Study Investigators of the EASL-CLIF Consortium. Development and validation of a prognostic score to predict mortality in patients with acute-on-chronic liver failure. J Hepatol 2014; 61 (05) 1038-1047
    CrossrefPubMedGoogle Scholar
  • 12 Bajaj JS, O'Leary JG, Reddy KR. et al; North American Consortium for the Study of End-Stage Liver Disease (NACSELD). Survival in infection-related acute-on-chronic liver failure is defined by extrahepatic organ failures. Hepatology 2014; 60 (01) 250-256
    CrossrefPubMedGoogle Scholar
  • 13 Hernaez R, Solà E, Moreau R, Ginès P. Acute-on-chronic liver failure: an update. Gut 2017; 66 (03) 541-553
    CrossrefPubMedGoogle Scholar
  • 14 Trebicka J, Fernandez J, Papp M. et al; PREDICT STUDY Group of the EASL-CLIF CONSORTIUM. PREDICT identifies precipitating events associated with the clinical course of acutely decompensated cirrhosis. J Hepatol 2021; 74 (05) 1097-1108
    CrossrefPubMedGoogle Scholar
  • 15 Arroyo V, Moreau R, Jalan R. Acute-on-chronic liver failure. N Engl J Med 2020; 382 (22) 2137-2145
    CrossrefPubMedGoogle Scholar
  • 16 Moreau R, Jalan R, Gines P. et al; CANONIC Study Investigators of the EASL–CLIF Consortium. Acute-on-chronic liver failure is a distinct syndrome that develops in patients with acute decompensation of cirrhosis. Gastroenterology 2013; 144 (07) 1426-1437 , 1437.e1–1437.e9
    CrossrefPubMedGoogle Scholar
  • 17 Siewers K, Abdullah SMOB, Sørensen RH, Nielsen FE. Time to administration of antibiotics and mortality in sepsis. J Am Coll Emerg Physicians Open 2021; 2 (03) e12435
    CrossrefPubMedGoogle Scholar
  • 18 Liu VX, Fielding-Singh V, Greene JD. et al. The timing of early antibiotics and hospital mortality in sepsis. Am J Respir Crit Care Med 2017; 196 (07) 856-863
    CrossrefPubMedGoogle Scholar
  • 19 Emerson P, McPeake J, O'Neill A. et al. The utility of scoring systems in critically ill cirrhotic patients admitted to a general intensive care unit. J Crit Care 2014; 29 (06) 1131.e1-1131.e6
    CrossrefPubMedGoogle Scholar
  • 20 Theocharidou E, Pieri G, Mohammad AO. et al. The Royal Free Hospital score: a calibrated prognostic model for patients with cirrhosis admitted to intensive care unit. Comparison with current models and CLIF-SOFA score. Am J Gastroenterol 2014; 109 (04) 554-562
    CrossrefPubMedGoogle Scholar
  • 21 Jalan R, Gines P, Olson JC. et al. Acute-on chronic liver failure. J Hepatol 2012; 57 (06) 1336-1348
    CrossrefPubMedGoogle Scholar
  • 22 Piano S, Bartoletti M, Tonon M. et al. Assessment of Sepsis-3 criteria and quick SOFA in patients with cirrhosis and bacterial infections. Gut 2018; 67 (10) 1892-1899
    CrossrefPubMedGoogle Scholar
  • 23 Patidar KR, Shaw J, Acharya C. et al. No association between Quick Sequential Organ Failure Assessment and outcomes of patients with cirrhosis and infections. Clin Gastroenterol Hepatol 2017; 15 (11) 1803-1804
    CrossrefPubMedGoogle Scholar
  • 24 Son J, Choi S, Huh JW. et al. The quick sepsis-related organ failure score has limited value for predicting adverse outcomes in sepsis patients with liver cirrhosis. Korean J Intern Med (Korean Assoc Intern Med) 2020; 35 (04) 861-872
    PubMedGoogle Scholar
  • 25 Müller M, Schefold JC, Leichtle AB. et al. qSOFA score not predictive of in-hospital mortality in emergency patients with decompensated liver cirrhosis. Med Klin Intensivmed Notf Med 2019; 114 (08) 724-732
    CrossrefPubMedGoogle Scholar
  • 26 Choi C, Choi DH, Spears GM. et al. Relationship between etiology of cirrhosis and survival among patients hospitalized in intensive care units. Mayo Clin Proc 2022; 97 (02) 274-284
    CrossrefPubMedGoogle Scholar
  • 27 Kim JH, Jun BG, Lee M. et al. Reappraisal of sepsis-3 and CLIF-SOFA as predictors of mortality in patients with cirrhosis and infection presenting to the emergency department: a multicenter study. Clin Mol Hepatol 2022; 28 (03) 540-552
    CrossrefPubMedGoogle Scholar
  • 28 Peng Y, Qi X, Guo X. Child-Pugh versus MELD score for the assessment of prognosis in liver cirrhosis: a systematic review and meta-analysis of observational studies. Medicine (Baltimore) 2016; 95 (08) e2877
    CrossrefPubMedGoogle Scholar
  • 29 Levesque E, Hoti E, Azoulay D. et al. Prospective evaluation of the prognostic scores for cirrhotic patients admitted to an intensive care unit. J Hepatol 2012; 56 (01) 95-102
    CrossrefPubMedGoogle Scholar
  • 30 O'Brien AJ, Welch CA, Singer M, Harrison DA. Prevalence and outcome of cirrhosis patients admitted to UK intensive care: a comparison against dialysis-dependent chronic renal failure patients. Intensive Care Med 2012; 38 (06) 991-1000
    CrossrefPubMedGoogle Scholar
  • 31 Das V, Boelle PY, Galbois A. et al. Cirrhotic patients in the medical intensive care unit: early prognosis and long-term survival. Crit Care Med 2010; 38 (11) 2108-2116
    CrossrefPubMedGoogle Scholar
  • 32 Olson JC, Karvellas CJ. Critical care management of the patient with cirrhosis awaiting liver transplant in the intensive care unit. Liver Transpl 2017; 23 (11) 1465-1476
    CrossrefPubMedGoogle Scholar
  • 33 Bajaj JS, O'Leary JG, Lai JC. et al. Acute-on-chronic liver failure clinical guidelines. Am J Gastroenterol 2022; 117 (02) 225-252
    CrossrefPubMedGoogle Scholar
  • 34 European Association for the Study of the Liver. Electronic address: easloffice@easloffice.eu; European Association for the Study of the Liver. EASL Clinical Practice Guidelines on the management of hepatic encephalopathy. J Hepatol 2022; 77 (03) 807-824
    CrossrefPubMedGoogle Scholar
  • 35 Drolz A, Jäger B, Wewalka M. et al. Clinical impact of arterial ammonia levels in ICU patients with different liver diseases. Intensive Care Med 2013; 39 (07) 1227-1237
    CrossrefPubMedGoogle Scholar
  • 36 Mehtani R, Garg S, Kajal K, Soni SL, Premkumar M. Neurological monitoring and sedation protocols in the liver intensive care unit. Metab Brain Dis 2022; 37 (05) 1291-1307
    CrossrefPubMedGoogle Scholar
  • 37 Sharma BC, Sharma P, Lunia MK, Srivastava S, Goyal R, Sarin SK. A randomized, double-blind, controlled trial comparing rifaximin plus lactulose with lactulose alone in treatment of overt hepatic encephalopathy. Am J Gastroenterol 2013; 108 (09) 1458-1463
    CrossrefPubMedGoogle Scholar
  • 38 Rose CF, Amodio P, Bajaj JS. et al. Hepatic encephalopathy: Novel insights into classification, pathophysiology and therapy. J Hepatol 2020; 73 (06) 1526-1547
    CrossrefPubMedGoogle Scholar
  • 39 Sharma BC, Sharma P, Agrawal A, Sarin SK. Secondary prophylaxis of hepatic encephalopathy: an open-label randomized controlled trial of lactulose versus placebo. Gastroenterology 2009; 137 (03) 885-891, 891.e1
    CrossrefPubMedGoogle Scholar
  • 40 Agrawal A, Sharma BC, Sharma P, Sarin SK. Secondary prophylaxis of hepatic encephalopathy in cirrhosis: an open-label, randomized controlled trial of lactulose, probiotics, and no therapy. Am J Gastroenterol 2012; 107 (07) 1043-1050
    CrossrefPubMedGoogle Scholar
  • 41 Kimer N, Krag A, Møller S, Bendtsen F, Gluud LL. Systematic review with meta-analysis: the effects of rifaximin in hepatic encephalopathy. Aliment Pharmacol Ther 2014; 40 (02) 123-132
    CrossrefPubMedGoogle Scholar
  • 42 Bass NM, Mullen KD, Sanyal A. et al. Rifaximin treatment in hepatic encephalopathy. N Engl J Med 2010; 362 (12) 1071-1081
    CrossrefPubMedGoogle Scholar
  • 43 Treggiari MM, Romand JA, Yanez ND. et al. Randomized trial of light versus deep sedation on mental health after critical illness. Crit Care Med 2009; 37 (09) 2527-2534
    CrossrefPubMedGoogle Scholar
  • 44 McKeage K, Perry CM. Propofol: a review of its use in intensive care sedation of adults. CNS Drugs 2003; 17 (04) 235-272
    CrossrefPubMedGoogle Scholar
  • 45 Kress JP, Pohlman AS, O'Connor MF, Hall JB. Daily interruption of sedative infusions in critically ill patients undergoing mechanical ventilation. N Engl J Med 2000; 342 (20) 1471-1477
    CrossrefPubMedGoogle Scholar
  • 46 Nadim MK, Durand F, Kellum JA. et al. Management of the critically ill patient with cirrhosis: a multidisciplinary perspective. J Hepatol 2016; 64 (03) 717-735
    CrossrefPubMedGoogle Scholar
  • 47 Guerit JM, Amantini A, Fischer C. et al; Members of the ISHEN Commission on Neurophysiological Investigations. Neurophysiological investigations of hepatic encephalopathy: ISHEN practice guidelines. Liver Int 2009; 29 (06) 789-796
    CrossrefPubMedGoogle Scholar
  • 48 Ginès P, Schrier RW. Renal failure in cirrhosis. N Engl J Med 2009; 361 (13) 1279-1290
    CrossrefPubMedGoogle Scholar
  • 49 Chayanupatkul M, Liangpunsakul S. Cirrhotic cardiomyopathy: review of pathophysiology and treatment. Hepatol Int 2014; 8 (03) 308-315
    CrossrefPubMedGoogle Scholar
  • 50 Malbrain ML, De Waele JJ, De Keulenaer BL. What every ICU clinician needs to know about the cardiovascular effects caused by abdominal hypertension. Anaesthesiol Intensive Ther 2015; 47 (04) 388-399
    CrossrefPubMedGoogle Scholar
  • 51 Aspesi M, Gamberoni C, Severgnini P. et al. The abdominal compartment syndrome. Clinical relevance. Minerva Anestesiol 2002; 68 (04) 138-146
    PubMedGoogle Scholar
  • 52 Nanchal R, Subramanian R, Karvellas CJ. et al. Guidelines for the management of adult acute and acute-on-chronic liver failure in the ICU: cardiovascular, endocrine, hematologic, pulmonary, and renal considerations. Crit Care Med 2020; 48 (03) e173-e191
    CrossrefPubMedGoogle Scholar
  • 53 Humphrey H, Hall J, Sznajder I, Silverstein M, Wood L. Improved survival in ARDS patients associated with a reduction in pulmonary capillary wedge pressure. Chest 1990; 97 (05) 1176-1180
    CrossrefPubMedGoogle Scholar
  • 54 Rosenberg AL, Dechert RE, Park PK, Bartlett RH. NIH NHLBI ARDS Network. Review of a large clinical series: association of cumulative fluid balance on outcome in acute lung injury: a retrospective review of the ARDSnet tidal volume study cohort. J Intensive Care Med 2009; 24 (01) 35-46
    CrossrefPubMedGoogle Scholar
  • 55 Brandstrup B, Tønnesen H, Beier-Holgersen R. et al; Danish Study Group on Perioperative Fluid Therapy. Effects of intravenous fluid restriction on postoperative complications: comparison of two perioperative fluid regimens: a randomized assessor-blinded multicenter trial. Ann Surg 2003; 238 (05) 641-648
    CrossrefPubMedGoogle Scholar
  • 56 Wiedemann HP, Wheeler AP, Bernard GR. et al; National Heart, Lung, and Blood Institute Acute Respiratory Distress Syndrome (ARDS) Clinical Trials Network. Comparison of two fluid-management strategies in acute lung injury. N Engl J Med 2006; 354 (24) 2564-2575
    CrossrefPubMedGoogle Scholar
  • 57 Rhodes A, Cusack RJ, Newman PJ, Grounds RM, Bennett ED. A randomised, controlled trial of the pulmonary artery catheter in critically ill patients. Intensive Care Med 2002; 28 (03) 256-264
    CrossrefPubMedGoogle Scholar
  • 58 De Backer D, Fagnoul D. Intensive care ultrasound: VI. Fluid responsiveness and shock assessment. Ann Am Thorac Soc 2014; 11 (01) 129-136
    CrossrefPubMedGoogle Scholar
  • 59 Levitov A, Frankel HL, Blaivas M. et al. Guidelines for the appropriate use of bedside general and cardiac ultrasonography in the evaluation of critically ill patients - Part II: Cardiac ultrasonography. Crit Care Med 2016; 44 (06) 1206-1227
    CrossrefPubMedGoogle Scholar
  • 60 Via G, Tavazzi G, Price S. Ten situations where inferior vena cava ultrasound may fail to accurately predict fluid responsiveness: a physiologically based point of view. Intensive Care Med 2016; 42 (07) 1164-1167
    CrossrefPubMedGoogle Scholar
  • 61 Porter TR, Shillcutt SK, Adams MS. et al. Guidelines for the use of echocardiography as a monitor for therapeutic intervention in adults: a report from the American Society of Echocardiography. J Am Soc Echocardiogr 2015; 28 (01) 40-56
    CrossrefPubMedGoogle Scholar
  • 62 Rowan KM, Angus DC, Bailey M. et al; PRISM Investigators. Early, goal-directed therapy for septic shock - a patient-level meta-analysis. N Engl J Med 2017; 376 (23) 2223-2234
    CrossrefPubMedGoogle Scholar
  • 63 Simonetto DA, Piccolo Serafim L, Gallo de Moraes A, Gajic O, Kamath PS. Management of sepsis in patients with cirrhosis: current evidence and practical approach. Hepatology 2019; 70 (01) 418-428
    CrossrefPubMedGoogle Scholar
  • 64 Casserly B, Phillips GS, Schorr C. et al. Lactate measurements in sepsis-induced tissue hypoperfusion: results from the Surviving Sepsis Campaign database. Crit Care Med 2015; 43 (03) 567-573
    CrossrefPubMedGoogle Scholar
  • 65 Lee SM, An WS. New clinical criteria for septic shock: serum lactate level as new emerging vital sign. J Thorac Dis 2016; 8 (07) 1388-1390
    CrossrefPubMedGoogle Scholar
  • 66 Ryoo SM, Lee J, Lee YS. et al. Lactate level versus lactate clearance for predicting mortality in patients with septic shock defined by Sepsis-3. Crit Care Med 2018; 46 (06) e489 –e495
    CrossrefPubMedGoogle Scholar
  • 67 Funk GC, Doberer D, Kneidinger N, Lindner G, Holzinger U, Schneeweiss B. Acid-base disturbances in critically ill patients with cirrhosis. Liver Int 2007; 27 (07) 901-909
    CrossrefPubMedGoogle Scholar
  • 68 Annane D, Siami S, Jaber S. et al; CRISTAL Investigators. Effects of fluid resuscitation with colloids vs crystalloids on mortality in critically ill patients presenting with hypovolemic shock: the CRISTAL randomized trial. JAMA 2013; 310 (17) 1809-1817
    CrossrefPubMedGoogle Scholar
  • 69 Finfer S, Bellomo R, Boyce N, French J, Myburgh J, Norton R. SAFE Study Investigators. A comparison of albumin and saline for fluid resuscitation in the intensive care unit. N Engl J Med 2004; 350 (22) 2247-2256
    CrossrefPubMedGoogle Scholar
  • 70 Caironi P, Tognoni G, Masson S. et al; ALBIOS Study Investigators. Albumin replacement in patients with severe sepsis or septic shock. N Engl J Med 2014; 370 (15) 1412-1421
    CrossrefPubMedGoogle Scholar
  • 71 Dellinger RP, Levy MM, Carlet JM. et al; International Surviving Sepsis Campaign Guidelines Committee; American Association of Critical-Care Nurses; American College of Chest Physicians; American College of Emergency Physicians; Canadian Critical Care Society European Society of Clinical Microbiology and Infectious Diseases;European Society of Intensive Care Medicine; European Respiratory Society; International Sepsis Forum; Japanese Association for Acute Medicine; Japanese Society of Intensive Care Medicine; Society of Critical Care Medicine; Society of Hospital Medicine; Surgical Infection Society; World Federation of Societies of Intensive and Critical Care Medicine. Surviving Sepsis Campaign: international guidelines for management of severe sepsis and septic shock: 2008. Crit Care Med 2008; 36 (01) 296-327
    CrossrefPubMedGoogle Scholar
  • 72 Rochwerg B, Alhazzani W, Sindi A. et al; Fluids in Sepsis and Septic Shock Group. Fluid resuscitation in sepsis: a systematic review and network meta-analysis. Ann Intern Med 2014; 161 (05) 347-355
    CrossrefPubMedGoogle Scholar
  • 73 Zou Y, Ma K, Xiong JB, Xi CH, Deng XJ. Comparison of the effects of albumin and crystalloid on mortality among patients with septic shock: systematic review with meta-analysis and trial sequential analysis. Sao Paulo Med J 2018; 136 (05) 421-432
    CrossrefPubMedGoogle Scholar
  • 74 Philips CA, Maiwall R, Sharma MK. et al. Comparison of 5% human albumin and normal saline for fluid resuscitation in sepsis induced hypotension among patients with cirrhosis (FRISC study): a randomized controlled trial. Hepatol Int 2021; 15 (04) 983-994
    CrossrefPubMedGoogle Scholar
  • 75 Maiwall R, Kumar A, Pasupuleti SSR. et al. A randomized-controlled trial comparing 20% albumin to plasmalyte in patients with cirrhosis and sepsis-induced hypotension [ALPS trial]. J Hepatol 2022; 77 (03) 670-682
    CrossrefPubMedGoogle Scholar
  • 76 Thévenot T, Bureau C, Oberti F. et al. Effect of albumin in cirrhotic patients with infection other than spontaneous bacterial peritonitis. A randomized trial. J Hepatol 2015; 62 (04) 822-830
    CrossrefPubMedGoogle Scholar
  • 77 Guevara M, Terra C, Nazar A. et al. Albumin for bacterial infections other than spontaneous bacterial peritonitis in cirrhosis. A randomized, controlled study. J Hepatol 2012; 57 (04) 759-765
    CrossrefPubMedGoogle Scholar
  • 78 Sauneuf B, Champigneulle B, Soummer A. et al. Increased survival of cirrhotic patients with septic shock. Crit Care 2013; 17 (02) R78
    CrossrefPubMedGoogle Scholar
  • 79 Myburgh JA, Finfer S, Bellomo R. et al; CHEST Investigators; Australian and New Zealand Intensive Care Society Clinical Trials Group. Hydroxyethyl starch or saline for fluid resuscitation in intensive care. N Engl J Med 2012; 367 (20) 1901-1911
    CrossrefPubMedGoogle Scholar
  • 80 Schortgen F, Lacherade JC, Bruneel F. et al. Effects of hydroxyethylstarch and gelatin on renal function in severe sepsis: a multicentre randomised study. Lancet 2001; 357 (9260): 911-916
    CrossrefPubMedGoogle Scholar
  • 81 Perner A, Haase N, Guttormsen AB. et al; 6S Trial Group; Scandinavian Critical Care Trials Group. Hydroxyethyl starch 130/0.42 versus Ringer's acetate in severe sepsis. N Engl J Med 2012; 367 (02) 124-134
    CrossrefPubMedGoogle Scholar
  • 82 Fernández J, Monteagudo J, Bargallo X. et al. A randomized unblinded pilot study comparing albumin versus hydroxyethyl starch in spontaneous bacterial peritonitis. Hepatology 2005; 42 (03) 627-634
    CrossrefPubMedGoogle Scholar
  • 83 Salerno F, Navickis RJ, Wilkes MM. Albumin infusion improves outcomes of patients with spontaneous bacterial peritonitis: a meta-analysis of randomized trials. Clin Gastroenterol Hepatol 2013; 11 (02) 123-30 .e1
    CrossrefPubMedGoogle Scholar
  • 84 Ortega R, Ginès P, Uriz J. et al. Terlipressin therapy with and without albumin for patients with hepatorenal syndrome: results of a prospective, nonrandomized study. Hepatology 2002; 36 (4, Pt 1): 941-948
    PubMedGoogle Scholar
  • 85 Bernardi M, Caraceni P, Navickis RJ, Wilkes MM. Albumin infusion in patients undergoing large-volume paracentesis: a meta-analysis of randomized trials. Hepatology 2012; 55 (04) 1172-1181
    CrossrefPubMedGoogle Scholar
  • 86 Singer M, Deutschman CS, Seymour CW. et al. The Third International Consensus Definitions for Sepsis and Septic Shock (Sepsis-3). JAMA 2016; 315 (08) 801-810
    Google Scholar
  • 87 Siddiqui MS, Stravitz RT. Intensive care unit management of patients with liver failure. Clin Liver Dis 2014; 18 (04) 957-978
    CrossrefPubMedGoogle Scholar
  • 88 Vincent JL, Biston P, Devriendt J, Brasseur A, De Backer D. Dopamine versus norepinephrine: is one better?. Minerva Anestesiol 2009; 75 (05) 333-337
    PubMedGoogle Scholar
  • 89 De Backer D, Biston P, Devriendt J. et al; SOAP II Investigators. Comparison of dopamine and norepinephrine in the treatment of shock. N Engl J Med 2010; 362 (09) 779-789
    CrossrefPubMedGoogle Scholar
  • 90 Avni T, Lador A, Lev S, Leibovici L, Paul M, Grossman A. Vasopressors for the treatment of septic shock: systematic review and meta-analysis. PLoS One 2015; 10 (08) e0129305
    CrossrefPubMedGoogle Scholar
  • 91 Wagener G, Bakker J. Vasopressin in cirrhosis and sepsis: physiology and clinical implications. Minerva Anestesiol 2015; 81 (12) 1377-1383
    PubMedGoogle Scholar
  • 92 Fede G, Spadaro L, Tomaselli T. et al. Adrenocortical dysfunction in liver disease: a systematic review. Hepatology 2012; 55 (04) 1282-1291
    CrossrefPubMedGoogle Scholar
  • 93 Piccolo Serafim L, Simonetto DA, Anderson AL. et al. Clinical effect of systemic steroids in patients with cirrhosis and septic shock. Shock 2021; 56 (06) 916-920
    CrossrefPubMedGoogle Scholar
  • 94 Venkatesh B, Finfer S, Cohen J. et al; ADRENAL Trial Investigators and the Australian–New Zealand Intensive Care Society Clinical Trials Group. Adjunctive glucocorticoid therapy in patients with septic shock. N Engl J Med 2018; 378 (09) 797-808
    CrossrefPubMedGoogle Scholar
  • 95 Annane D, Renault A, Brun-Buisson C. et al; CRICS-TRIGGERSEP Network. Hydrocortisone plus fludrocortisone for adults with septic shock. N Engl J Med 2018; 378 (09) 809-818
    CrossrefPubMedGoogle Scholar
  • 96 Gibbs JT, Louissaint J, Tapper EB. Rate of successful extubation in mechanically ventilated patients with cirrhosis and hepatic coma. Dig Dis Sci 2022; 67 (11) 5336-5344
    CrossrefPubMedGoogle Scholar
  • 97 Brower RG, Matthay MA, Morris A, Schoenfeld D, Thompson BT, Wheeler A. Acute Respiratory Distress Syndrome Network. Ventilation with lower tidal volumes as compared with traditional tidal volumes for acute lung injury and the acute respiratory distress syndrome. N Engl J Med 2000; 342 (18) 1301-1308
    CrossrefPubMedGoogle Scholar
  • 98 Plataki M, Hubmayr RD. The physical basis of ventilator-induced lung injury. Expert Rev Respir Med 2010; 4 (03) 373-385
    CrossrefPubMedGoogle Scholar
  • 99 Waller EA, Aduen JF, Kramer DJ. et al. Safety of percutaneous dilatational tracheostomy with direct bronchoscopic guidance for solid organ allograft recipients. Mayo Clin Proc 2007; 82 (12) 1502-1508
    CrossrefPubMedGoogle Scholar
  • 100 Carvalho L, Parise ER. Evaluation of nutritional status of nonhospitalized patients with liver cirrhosis. Arq Gastroenterol 2006; 43 (04) 269-274
    CrossrefPubMedGoogle Scholar
  • 101 Sam J, Nguyen GC. Protein-calorie malnutrition as a prognostic indicator of mortality among patients hospitalized with cirrhosis and portal hypertension. Liver Int 2009; 29 (09) 1396-1402
    CrossrefPubMedGoogle Scholar
  • 102 Cheung K, Lee SS, Raman M. Prevalence and mechanisms of malnutrition in patients with advanced liver disease, and nutrition management strategies. Clin Gastroenterol Hepatol 2012; 10 (02) 117-125
    CrossrefPubMedGoogle Scholar
  • 103 Tandon P, Raman M, Mourtzakis M, Merli M. A practical approach to nutritional screening and assessment in cirrhosis. Hepatology 2017; 65 (03) 1044-1057
    CrossrefPubMedGoogle Scholar
  • 104 McClave SA, Taylor BE, Martindale RG. et al; Society of Critical Care Medicine; American Society for Parenteral and Enteral Nutrition. Guidelines for the provision and assessment of nutrition support therapy in the adult critically ill patient: Society of Critical Care Medicine (SCCM) and American Society for Parenteral and Enteral Nutrition (A.S.P.E.N.). JPEN J Parenter Enteral Nutr 2016; 40 (02) 159-211
    CrossrefPubMedGoogle Scholar
  • 105 Merli M, Riggio O, Dally L. Does malnutrition affect survival in cirrhosis? PINC (Policentrica Italiana Nutrizione Cirrosi). Hepatology 1996; 23 (05) 1041-1046
    CrossrefPubMedGoogle Scholar
  • 106 Mendenhall CL, Moritz TE, Roselle GA. et al. A study of oral nutritional support with oxandrolone in malnourished patients with alcoholic hepatitis: results of a Department of Veterans Affairs cooperative study. Hepatology 1993; 17 (04) 564-576
    CrossrefPubMedGoogle Scholar
  • 107 Cabré E, Rodríguez-Iglesias P, Caballería J. et al. Short- and long-term outcome of severe alcohol-induced hepatitis treated with steroids or enteral nutrition: a multicenter randomized trial. Hepatology 2000; 32 (01) 36-42
    CrossrefPubMedGoogle Scholar
  • 108 Koretz RL, Avenell A, Lipman TO. Nutritional support for liver disease. Cochrane Database Syst Rev 2012; 2012 (05) CD008344
    PubMedGoogle Scholar
  • 109 Moreno C, Deltenre P, Senterre C. et al. Intensive enteral nutrition is ineffective for patients with severe alcoholic hepatitis treated with corticosteroids. Gastroenterology 2016; 150 (04) 903-10.e8
    CrossrefPubMedGoogle Scholar
  • 110 Plauth M, Cabré E, Riggio O. et al; DGEM (German Society for Nutritional Medicine) ESPEN (European Society for Parenteral and Enteral Nutrition). ESPEN guidelines on enteral nutrition: liver disease. Clin Nutr 2006; 25 (02) 285-294
    CrossrefPubMedGoogle Scholar
  • 111 Juakiem W, Torres DM, Harrison SA. Nutrition in cirrhosis and chronic liver disease. Clin Liver Dis 2014; 18 (01) 179-190
    CrossrefPubMedGoogle Scholar
  • 112 European Association for the Study of the Liver. Electronic address: easloffice@easloffice.eu; European Association for the Study of the Liver. EASL clinical practice guidelines on nutrition in chronic liver disease. J Hepatol 2019; 70 (01) 172-193
    CrossrefPubMedGoogle Scholar
  • 113 Targownik LE, Fisher DA, Saini SD. AGA clinical practice update on de-prescribing of proton pump inhibitors: expert review. Gastroenterology 2022; 162 (04) 1334-1342
    CrossrefPubMedGoogle Scholar
  • 114 Tapper EB, Henderson JB, Parikh ND, Ioannou GN, Lok AS. Incidence of and risk factors for hepatic encephalopathy in a population-based cohort of Americans with cirrhosis. Hepatol Commun 2019; 3 (11) 1510-1519
    CrossrefPubMedGoogle Scholar
  • 115 Trikudanathan G, Israel J, Cappa J, O'Sullivan DM. Association between proton pump inhibitors and spontaneous bacterial peritonitis in cirrhotic patients - a systematic review and meta-analysis. Int J Clin Pract 2011; 65 (06) 674-678
    CrossrefPubMedGoogle Scholar
  • 116 Bajaj JS, Zadvornova Y, Heuman DM. et al. Association of proton pump inhibitor therapy with spontaneous bacterial peritonitis in cirrhotic patients with ascites. Am J Gastroenterol 2009; 104 (05) 1130-1134
    CrossrefPubMedGoogle Scholar
  • 117 Bajaj JS, Ananthakrishnan AN, Hafeezullah M. et al. Clostridium difficile is associated with poor outcomes in patients with cirrhosis: a national and tertiary center perspective. Am J Gastroenterol 2010; 105 (01) 106-113
    CrossrefPubMedGoogle Scholar
  • 118 Bajaj JS, Ratliff SM, Heuman DM, Lapane KL. Proton pump inhibitors are associated with a high rate of serious infections in veterans with decompensated cirrhosis. Aliment Pharmacol Ther 2012; 36 (09) 866-874
    CrossrefPubMedGoogle Scholar
  • 119 Mahmud N, Serper M, Taddei TH, Kaplan DE. The association between proton pump inhibitor exposure and key liver-related outcomes in patients with cirrhosis: a Veterans Affairs Cohort Study. Gastroenterology 2022; 163 (01) 257-269 .e6
    CrossrefPubMedGoogle Scholar
  • 120 Weersink RA, Bouma M, Burger DM. et al. Safe use of proton pump inhibitors in patients with cirrhosis. Br J Clin Pharmacol 2018; 84 (08) 1806-1820
    CrossrefPubMedGoogle Scholar
  • 121 Cholongitas E, Senzolo M, Patch D, Shaw S, O'Beirne J, Burroughs AK. Cirrhotics admitted to intensive care unit: the impact of acute renal failure on mortality. Eur J Gastroenterol Hepatol 2009; 21 (07) 744-750
    CrossrefPubMedGoogle Scholar
  • 122 du Cheyron D, Bouchet B, Parienti JJ, Ramakers M, Charbonneau P. The attributable mortality of acute renal failure in critically ill patients with liver cirrhosis. Intensive Care Med 2005; 31 (12) 1693-1699
    CrossrefPubMedGoogle Scholar
  • 123 Hampel H, Bynum GD, Zamora E, El-Serag HB. Risk factors for the development of renal dysfunction in hospitalized patients with cirrhosis. Am J Gastroenterol 2001; 96 (07) 2206-2210
    CrossrefPubMedGoogle Scholar
  • 124 Davenport A, Sheikh MF, Lamb E, Agarwal B, Jalan R. Acute kidney injury in acute-on-chronic liver failure: where does hepatorenal syndrome fit?. Kidney Int 2017; 92 (05) 1058-1070
    CrossrefPubMedGoogle Scholar
  • 125 Allegretti AS, Solà E, Ginès P. Clinical application of kidney biomarkers in cirrhosis. Am J Kidney Dis 2020; 76 (05) 710-719
    CrossrefPubMedGoogle Scholar
  • 126 Angeli P, Ginès P, Wong F. et al. Diagnosis and management of acute kidney injury in patients with cirrhosis: revised consensus recommendations of the International Club of Ascites. J Hepatol 2015; 62 (04) 968-974
    CrossrefPubMedGoogle Scholar
  • 127 Garcia-Tsao G, Parikh CR, Viola A. Acute kidney injury in cirrhosis. Hepatology 2008; 48 (06) 2064-2077
    CrossrefPubMedGoogle Scholar
  • 128 Facciorusso A, Chandar AK, Murad MH. et al. Comparative efficacy of pharmacological strategies for management of type 1 hepatorenal syndrome: a systematic review and network meta-analysis. Lancet Gastroenterol Hepatol 2017; 2 (02) 94-102
    CrossrefPubMedGoogle Scholar
  • 129 Gaudry S, Hajage D, Schortgen F. et al; AKIKI Study Group. Initiation strategies for renal-replacement therapy in the intensive care unit. N Engl J Med 2016; 375 (02) 122-133
    CrossrefPubMedGoogle Scholar
  • 130 Zarbock A, Kellum JA, Schmidt C. et al. Effect of early vs delayed initiation of renal replacement therapy on mortality in critically ill patients with acute kidney injury: the ELAIN Randomized Clinical Trial. JAMA 2016; 315 (20) 2190-2199
    CrossrefPubMedGoogle Scholar
  • 131 Ginès P, Solà E, Angeli P, Wong F, Nadim MK, Kamath PS. Hepatorenal syndrome. Nat Rev Dis Primers 2018; 4 (01) 23
    CrossrefPubMedGoogle Scholar
  • 132 Huelin P, Solà E, Elia C. et al. Neutrophil gelatinase-associated lipocalin for assessment of acute kidney injury in cirrhosis: a prospective study. Hepatology 2019; 70 (01) 319-333
    CrossrefPubMedGoogle Scholar
  • 133 Allegretti AS, Parada XV, Endres P. et al; HRS-HARMONY Study Investigators. Urinary NGAL as a diagnostic and prognostic marker for acute kidney injury in cirrhosis: a prospective study. Clin Transl Gastroenterol 2021; 12 (05) e00359
    CrossrefPubMedGoogle Scholar
  • 134 Velez JCQ, Petkovich B, Karakala N, Huggins JT. Point-of-care echocardiography unveils misclassification of acute kidney injury as hepatorenal syndrome. Am J Nephrol 2019; 50 (03) 204-211
    CrossrefPubMedGoogle Scholar
  • 135 Del Risco-Zevallos J, Andújar AM, Piñeiro G. et al. Management of acute renal replacement therapy in critically ill cirrhotic patients. Clin Kidney J 2022; 15 (06) 1060-1070
    PubMedGoogle Scholar
  • 136 Gonwa TA, Wadei HM. The challenges of providing renal replacement therapy in decompensated liver cirrhosis. Blood Purif 2012; 33 1-3 144-148
    CrossrefPubMedGoogle Scholar
  • 137 Jones BE, Allegretti AS, Pose E. et al. Renal replacement therapy for acute kidney injury in severe alcohol-associated hepatitis as a bridge to transplant or recovery. Dig Dis Sci 2022; 67 (02) 697-707
    CrossrefPubMedGoogle Scholar
  • 138 Bagshaw SM, Wald R, Adhikari NKJ. et al; STARRT-AKI Investigators; Canadian Critical Care Trials Group; Australian and New Zealand Intensive Care Society Clinical Trials Group; United Kingdom Critical Care Research Group; Canadian Nephrology Trials Network; Irish Critical Care Trials Group. Timing of initiation of renal-replacement therapy in acute kidney injury. N Engl J Med 2020; 383 (03) 240-251
    CrossrefPubMedGoogle Scholar
  • 139 Gaudry S, Hajage D, Martin-Lefevre L. et al. Comparison of two delayed strategies for renal replacement therapy initiation for severe acute kidney injury (AKIKI 2): a multicentre, open-label, randomised, controlled trial. Lancet 2021; 397 (10281): 1293-1300
    CrossrefPubMedGoogle Scholar
  • 140 European Association for the Study of the Liver. Electronic address: easloffice@easloffice.eu; European Association for the Study of the Liver. EASL clinical practice guidelines for the management of patients with decompensated cirrhosis. J Hepatol 2018; 69 (02) 406-460
    CrossrefPubMedGoogle Scholar
  • 141 Staufer K, Roedl K, Kivaranovic D. et al. Renal replacement therapy in critically ill liver cirrhotic patients-outcome and clinical implications. Liver Int 2017; 37 (06) 843-850
    CrossrefPubMedGoogle Scholar
  • 142 Witzke O, Baumann M, Patschan D. et al. Which patients benefit from hemodialysis therapy in hepatorenal syndrome?. J Gastroenterol Hepatol 2004; 19 (12) 1369-1373
    CrossrefPubMedGoogle Scholar
  • 143 Wong LP, Blackley MP, Andreoni KA, Chin H, Falk RJ, Klemmer PJ. Survival of liver transplant candidates with acute renal failure receiving renal replacement therapy. Kidney Int 2005; 68 (01) 362-370
    CrossrefPubMedGoogle Scholar
  • 144 Zhang W, Bai M, Yu Y. et al. Safety and efficacy of regional citrate anticoagulation for continuous renal replacement therapy in liver failure patients: a systematic review and meta-analysis. Crit Care 2019; 23 (01) 22
    CrossrefPubMedGoogle Scholar
  • 145 Klingele M, Stadler T, Fliser D, Speer T, Groesdonk HV, Raddatz A. Long-term continuous renal replacement therapy and anticoagulation with citrate in critically ill patients with severe liver dysfunction. Crit Care 2017; 21 (01) 294
    CrossrefPubMedGoogle Scholar
  • 146 European Association for the Study of the Liver. EASL clinical practice guidelines on the management of ascites, spontaneous bacterial peritonitis, and hepatorenal syndrome in cirrhosis. J Hepatol 2010; 53 (03) 397-417
    CrossrefPubMedGoogle Scholar
  • 147 Angeli P, Wong F, Watson H, Ginès P. CAPPS Investigators. Hyponatremia in cirrhosis: results of a patient population survey. Hepatology 2006; 44 (06) 1535-1542
    CrossrefPubMedGoogle Scholar
  • 148 Flores B, Trivedi HD, Robson SC, Bonder A. Hemostasis, bleeding and thrombosis in liver disease. J Transl Sci 2017; 3 (03) 3
    CrossrefPubMedGoogle Scholar
  • 149 Blasi A, Calvo A, Prado V. et al. Coagulation failure in patients with acute-on-chronic liver failure and decompensated cirrhosis: beyond the international normalized ratio. Hepatology 2018; 68 (06) 2325-2337
    CrossrefPubMedGoogle Scholar
  • 150 O'Leary JG, Greenberg CS, Patton HM, Caldwell SH. AGA Clinical Practice Update: coagulation in cirrhosis. Gastroenterology 2019; 157 (01) 34-43 .e1
    CrossrefPubMedGoogle Scholar
  • 151 Kor DJ, Gajic O. Blood product transfusion in the critical care setting. Curr Opin Crit Care 2010; 16 (04) 309-316
    CrossrefPubMedGoogle Scholar
  • 152 European Association for the Study of the Liver. Electronic address: easloffice@easloffice.eu; European Association for the Study of the Liver. EASL Clinical Practice Guidelines on prevention and management of bleeding and thrombosis in patients with cirrhosis. J Hepatol 2022; 76 (05) 1151-1184
    CrossrefPubMedGoogle Scholar
  • 153 Northup PG, Garcia-Pagan JC, Garcia-Tsao G. et al. Vascular liver disorders, portal vein thrombosis, and procedural bleeding in patients with liver disease: 2020 Practice Guidance by the American Association for the Study of Liver Diseases. Hepatology 2021; 73 (01) 366-413
    CrossrefPubMedGoogle Scholar
  • 154 Villanueva C, Colomo A, Bosch A. et al. Transfusion strategies for acute upper gastrointestinal bleeding. N Engl J Med 2013; 368 (01) 11-21
    CrossrefPubMedGoogle Scholar
  • 155 Tripodi A, Primignani M, Chantarangkul V. et al. Thrombin generation in patients with cirrhosis: the role of platelets. Hepatology 2006; 44 (02) 440-445
    CrossrefPubMedGoogle Scholar
  • 156 Caldwell SH, Hoffman M, Lisman T. et al; Coagulation in Liver Disease Group. Coagulation disorders and hemostasis in liver disease: pathophysiology and critical assessment of current management. Hepatology 2006; 44 (04) 1039-1046
    CrossrefPubMedGoogle Scholar
  • 157 Seeff LB, Everson GT, Morgan TR. et al; HALT–C Trial Group. Complication rate of percutaneous liver biopsies among persons with advanced chronic liver disease in the HALT-C trial. Clin Gastroenterol Hepatol 2010; 8 (10) 877-883
    CrossrefPubMedGoogle Scholar
  • 158 West J, Card TR. Reduced mortality rates following elective percutaneous liver biopsies. Gastroenterology 2010; 139 (04) 1230-1237
    CrossrefPubMedGoogle Scholar
  • 159 Moulis G, Bagheri H, Sailler L. et al; French Association of PharmacoVigilance Centers. Are adverse drug reaction patterns different between romiplostim and eltrombopag? 2009-2013 French PharmacoVigilance assessment. Eur J Intern Med 2014; 25 (08) 777-780
    CrossrefPubMedGoogle Scholar
  • 160 Gunawan B, Runyon B. The efficacy and safety of epsilon-aminocaproic acid treatment in patients with cirrhosis and hyperfibrinolysis. Aliment Pharmacol Ther 2006; 23 (01) 115-120
    CrossrefPubMedGoogle Scholar
  • 161 Villa E, Cammà C, Marietta M. et al. Enoxaparin prevents portal vein thrombosis and liver decompensation in patients with advanced cirrhosis. Gastroenterology 2012; 143 (05) 1253-1260.e4
    CrossrefPubMedGoogle Scholar
  • 162 Francoz C, Belghiti J, Vilgrain V. et al. Splanchnic vein thrombosis in candidates for liver transplantation: usefulness of screening and anticoagulation. Gut 2005; 54 (05) 691-697
    CrossrefPubMedGoogle Scholar
  • 163 Intagliata NM, Henry ZH, Shah N, Lisman T, Caldwell SH, Northup PG. Prophylactic anticoagulation for venous thromboembolism in hospitalized cirrhosis patients is not associated with high rates of gastrointestinal bleeding. Liver Int 2014; 34 (01) 26-32
    CrossrefPubMedGoogle Scholar
  • 164 Barclay SM, Jeffres MN, Nguyen K, Nguyen T. Evaluation of pharmacologic prophylaxis for venous thromboembolism in patients with chronic liver disease. Pharmacotherapy 2013; 33 (04) 375-382
    CrossrefPubMedGoogle Scholar
  • 165 Tsai MH, Peng YS, Chen YC. et al. Adrenal insufficiency in patients with cirrhosis, severe sepsis and septic shock. Hepatology 2006; 43 (04) 673-681
    CrossrefPubMedGoogle Scholar
  • 166 Fernández J, Escorsell A, Zabalza M. et al. Adrenal insufficiency in patients with cirrhosis and septic shock: effect of treatment with hydrocortisone on survival. Hepatology 2006; 44 (05) 1288-1295
    CrossrefPubMedGoogle Scholar
  • 167 Arabi YM, Aljumah A, Dabbagh O. et al. Low-dose hydrocortisone in patients with cirrhosis and septic shock: a randomized controlled trial. CMAJ 2010; 182 (18) 1971-1977
    CrossrefPubMedGoogle Scholar
  • 168 Finfer S, Chittock DR, Su SY. et al; NICE-SUGAR Study Investigators. Intensive versus conventional glucose control in critically ill patients. N Engl J Med 2009; 360 (13) 1283-1297
    CrossrefPubMedGoogle Scholar
  • 169 Bajaj JS, O'Leary JG, Reddy KR. et al; NACSELD. Second infections independently increase mortality in hospitalized patients with cirrhosis: the North American consortium for the study of end-stage liver disease (NACSELD) experience. Hepatology 2012; 56 (06) 2328-2335
    CrossrefPubMedGoogle Scholar
  • 170 Bajaj JS, O'Leary JG, Wong F, Reddy KR, Kamath PS. Bacterial infections in end-stage liver disease: current challenges and future directions. Gut 2012; 61 (08) 1219-1225
    CrossrefPubMedGoogle Scholar
  • 171 Fernández J, Acevedo J, Castro M. et al. Prevalence and risk factors of infections by multiresistant bacteria in cirrhosis: a prospective study. Hepatology 2012; 55 (05) 1551-1561
    CrossrefPubMedGoogle Scholar
  • 172 Jalan R, Fernandez J, Wiest R. et al. Bacterial infections in cirrhosis: a position statement based on the EASL Special Conference 2013. J Hepatol 2014; 60 (06) 1310-1324
    CrossrefPubMedGoogle Scholar
  • 173 Bajaj JS, Reddy RK, Tandon P. et al. Prediction of fungal infection development and their impact on survival using the NACSELD cohort. Am J Gastroenterol 2018; 113 (04) 556-563
    CrossrefPubMedGoogle Scholar
  • 174 Fernández J, Ruiz del Arbol L, Gómez C. et al. Norfloxacin vs ceftriaxone in the prophylaxis of infections in patients with advanced cirrhosis and hemorrhage. Gastroenterology 2006; 131 (04) 1049-1056 , quiz 1285
    CrossrefPubMedGoogle Scholar
  • 175 Ginés P, Rimola A, Planas R. et al. Norfloxacin prevents spontaneous bacterial peritonitis recurrence in cirrhosis: results of a double-blind, placebo-controlled trial. Hepatology 1990; 12 4, Pt 1 716-724
    CrossrefPubMedGoogle Scholar
  • 176 Cannon MD, Martin P, Carrion AF. Bacterial infection in patients with cirrhosis: don't get bugged to death. Dig Dis Sci 2020; 65 (01) 31-37
    CrossrefPubMedGoogle Scholar
  • 177 Saab S, Hernandez JC, Chi AC, Tong MJ. Oral antibiotic prophylaxis reduces spontaneous bacterial peritonitis occurrence and improves short-term survival in cirrhosis: a meta-analysis. Am J Gastroenterol 2009; 104 (04) 993-1001 , quiz 1002
    CrossrefPubMedGoogle Scholar
  • 178 Sort P, Navasa M, Arroyo V. et al. Effect of intravenous albumin on renal impairment and mortality in patients with cirrhosis and spontaneous bacterial peritonitis. N Engl J Med 1999; 341 (06) 403-409
    CrossrefPubMedGoogle Scholar
  • 179 Vergis N, Atkinson SR, Knapp S. et al. In patients with severe alcoholic hepatitis, prednisolone increases susceptibility to infection and infection-related mortality, and is associated with high circulating levels of bacterial DNA. Gastroenterology 2017; 152 (05) 1068-1077.e4
    CrossrefPubMedGoogle Scholar
  • 180 Flamm SL. Rifaximin treatment for reduction of risk of overt hepatic encephalopathy recurrence. Therap Adv Gastroenterol 2011; 4 (03) 199-206
    CrossrefPubMedGoogle Scholar
  • 181 Ayares G, Idalsoaga F, Díaz LA, Arnold J, Arab JP. Current medical treatment for alcohol-associated liver disease. J Clin Exp Hepatol 2022; 12 (05) 1333-1348
    CrossrefPubMedGoogle Scholar
  • 182 Engelmann C, Berg T. Management of infectious complications associated with acute-on-chronic liver failure. Visc Med 2018; 34 (04) 261-268
    CrossrefPubMedGoogle Scholar
  • 183 Piano S, Fasolato S, Salinas F. et al. The empirical antibiotic treatment of nosocomial spontaneous bacterial peritonitis: results of a randomized, controlled clinical trial. Hepatology 2016; 63 (04) 1299-1309
    CrossrefPubMedGoogle Scholar
  • 184 Rivers E, Nguyen B, Havstad S. et al; Early Goal-Directed Therapy Collaborative Group. Early goal-directed therapy in the treatment of severe sepsis and septic shock. N Engl J Med 2001; 345 (19) 1368-1377
    CrossrefPubMedGoogle Scholar
  • 185 Fernandez J, Arroyo V. Bacterial infections in cirrhosis: a growing problem with significant implications. Clin Liver Dis (Hoboken) 2013; 2 (03) 102-105
    CrossrefPubMedGoogle Scholar
  • 186 Merli M, Lucidi C, Di Gregorio V. et al. An empirical broad spectrum antibiotic therapy in health-care-associated infections improves survival in patients with cirrhosis: a randomized trial. Hepatology 2016; 63 (05) 1632-1639
    CrossrefPubMedGoogle Scholar
  • 187 McDonald LC, Gerding DN, Johnson S. et al. Clinical practice guidelines for Clostridium difficile infection in adults and children: 2017 update by the Infectious Diseases Society of America (IDSA) and Society for Healthcare Epidemiology of America (SHEA). Clin Infect Dis 2018; 66 (07) 987-994
    CrossrefPubMedGoogle Scholar